Suppliers and packagers for LOVENOX

LOVENOX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164	NDA	Sanofi-Aventis U.S. LLC	0075-0620-40	10 CELLO PACK in 1 CARTON (0075-0620-40) / 1 SYRINGE in 1 CELLO PACK (0075-0620-01) / .4 mL in 1 SYRINGE	1993-03-29
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164	NDA	Sanofi-Aventis U.S. LLC	0075-0621-60	10 CELLO PACK in 1 CARTON (0075-0621-60) / 1 SYRINGE in 1 CELLO PACK (0075-0621-01) / .6 mL in 1 SYRINGE	1993-03-29
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164	NDA	Sanofi-Aventis U.S. LLC	0075-0622-80	10 CELLO PACK in 1 CARTON (0075-0622-80) / 1 SYRINGE in 1 CELLO PACK (0075-0622-01) / .8 mL in 1 SYRINGE	1993-03-29
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164	NDA	Sanofi-Aventis U.S. LLC	0075-0623-00	10 CELLO PACK in 1 CARTON (0075-0623-00) / 1 SYRINGE in 1 CELLO PACK (0075-0623-03) / 1 mL in 1 SYRINGE	1993-03-29
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164	NDA	Sanofi-Aventis U.S. LLC	0075-0626-03	1 VIAL, MULTI-DOSE in 1 CARTON (0075-0626-03) / 3 mL in 1 VIAL, MULTI-DOSE	1993-03-29

Lovenox Suppliers: Manufacturing Landscape and Supply Chain Dynamics

Last updated: February 19, 2026

This report details the primary suppliers and manufacturing capabilities for Lovenox (enoxaparin sodium), a low molecular weight heparin (LMWH) anticoagulant. Analysis focuses on current and historical key manufacturers, regulatory compliance, and potential supply chain risks.

Who Manufactures Lovenox and Its Active Pharmaceutical Ingredient (API)?

The production of Lovenox involves two critical components: the active pharmaceutical ingredient (API), enoxaparin sodium, and the finished drug product. Historically, Sanofi has been the primary originator and manufacturer of Lovenox. However, the market has evolved with the emergence of generic versions and biosimil competitors, particularly following patent expiries in key regions.

API Manufacturing

Enoxaparin sodium is derived from unfractionated heparin through a depolymerization process. This complex chemical synthesis requires specialized facilities and stringent quality control.

• Originator API Production: Sanofi, through its manufacturing sites, has historically controlled a significant portion of enoxaparin sodium API production for its branded Lovenox product. Specific site details are proprietary, but their expertise in heparin-derived products is well-established.
• Generic API Suppliers: Several companies have entered the API market for enoxaparin sodium, primarily to supply generic manufacturers. These suppliers operate under strict regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Identifying all API suppliers publicly is challenging due to the proprietary nature of supply agreements. However, regulatory filings and industry reports indicate:
  • Heparin Sourcing Challenges: The ultimate source of heparin is animal intestine, typically porcine. This reliance on animal-derived starting materials introduces inherent supply chain vulnerabilities related to animal health, sourcing, and traceability. Changes in heparin sourcing, such as the 2008 heparin contamination crisis, have highlighted the need for robust supplier qualification and testing.
  • Key API Development: Companies specializing in complex biologics and complex generics have invested in enoxaparin API capabilities. For example, certain Indian and Chinese pharmaceutical ingredient manufacturers have developed expertise in heparin processing. However, specific company names as direct, disclosed enoxaparin API suppliers to the global market are not always publicly available through routine channels due to B2B contractual confidentiality.

Finished Drug Product Manufacturing

The formulation and filling of enoxaparin sodium into injectable solutions are conducted at finished drug product (FDP) manufacturing sites.

• Sanofi (Branded Lovenox): Sanofi manufactures branded Lovenox at its global pharmaceutical production facilities. These sites adhere to Current Good Manufacturing Practices (cGMP) and are subject to regular inspections by regulatory authorities.
  • Example Facility: Sanofi has historically utilized its facility in Vitry-sur-Seine, France, for the production of certain heparin-based products. Global manufacturing networks involve multiple sites for risk mitigation and market supply.
• Generic and Biosimilar Manufacturers: Following patent expirations, numerous pharmaceutical companies have launched generic versions of enoxaparin sodium, and biosimilar versions are also gaining traction. These companies either manufacture in-house or contract with third-party contract manufacturing organizations (CMOs).
  • Major Generic/Biosimilar Players: Companies that have developed or marketed generic/biosimilar enoxaparin sodium include:
    • Pfizer: Markets enoxaparin sodium (marketed as Infusion).
    • Fresenius Kabi: Offers enoxaparin sodium injection.
    • Teva Pharmaceuticals: A significant player in the generic drug market, also produces enoxaparin sodium.
    • Sandoz (Novartis): Known for biosimil development, also has a presence in the enoxaparin sodium market.
    • Momenta Pharmaceuticals (now acquired by Johnson & Johnson): Was a key player in developing enoxaparin sodium generics and biosimil-like products.
  • Contract Manufacturing Organizations (CMOs): The use of CMOs is common in the pharmaceutical industry for FDP manufacturing. These specialized facilities provide aseptic filling, packaging, and labeling services. Companies developing generic enoxaparin may contract with CMOs that have specific expertise in injectable sterile products and heparin derivatives. Identifying specific CMOs for enoxaparin production is often confidential information tied to supply contracts. However, major CMOs with sterile injectables capabilities in North America, Europe, and Asia would be potential candidates.

Regulatory Landscape and Compliance

The manufacture of enoxaparin sodium is heavily regulated due to its parenteral administration and the complex manufacturing process. Regulatory bodies scrutinize API sourcing, manufacturing processes, product quality, and post-market surveillance.

• FDA Oversight (U.S.): The FDA approves enoxaparin sodium products based on rigorous review of efficacy, safety, and manufacturing quality. Generic approvals require demonstrating bioequivalence to the reference listed drug (Lovenox). Biosimilar approvals require demonstrating high similarity to the reference product with no clinically meaningful differences.
  • ANDA Filings: Abbreviated New Drug Applications (ANDAs) for generic enoxaparin sodium require detailed information on API sourcing, manufacturing, and quality control.
  • BPCIA Filings: Biologics License Applications (BLAs) are used for biosimilar enoxaparin sodium, requiring extensive analytical, preclinical, and clinical data.
• EMA Oversight (Europe): The EMA uses a similar but distinct regulatory framework.
  • Marketing Authorisation Applications (MAA): Companies seeking to market generic or biosimilar enoxaparin sodium in the EU must obtain a Marketing Authorisation.
  • Inspections: Both FDA and EMA conduct pre-approval and routine cGMP inspections of manufacturing facilities, including API and FDP sites, globally.
• Heparin Sourcing Regulations: Regulations specifically address the sourcing of heparin from animal products to ensure safety and prevent contamination. This includes requirements for:
  • Traceability: Documenting the origin of raw materials.
  • Testing: Implementing comprehensive testing for contaminants, such as oversulfated chondroitin sulfate (OSCS).
  • Supplier Audits: Regular audits of heparin API suppliers.

Supply Chain Dynamics and Risk Factors

The supply chain for enoxaparin sodium is complex and carries specific risks that can impact availability and cost.

Key Risk Factors

• Animal-Derived Starting Material: The primary risk stems from the reliance on porcine intestinal heparin.
  • Geopolitical and Animal Health Factors: Outbreaks of animal diseases (e.g., African Swine Fever), changes in livestock farming practices, or geopolitical instability in major heparin-producing regions (historically China and India) can disrupt supply.
  • Ethical and Religious Considerations: Sourcing from specific animal populations can be subject to ethical concerns and religious restrictions, affecting supply availability.
• Manufacturing Complexity: The depolymerization and purification of heparin are technically demanding processes.
  • Specialized Facilities: Few companies possess the necessary specialized equipment and expertise for enoxaparin API production.
  • Batch-to-Batch Consistency: Ensuring consistent molecular weight distribution and biological activity is crucial and requires rigorous process control.
• Regulatory Hurdles: The stringent regulatory requirements for sterile injectables and complex generics/biosimil can create barriers to entry and extend product development timelines.
  • Import Alerts and Warning Letters: Regulatory actions against manufacturing facilities can lead to product shortages.
• Market Competition and Pricing Pressures: The introduction of multiple generic and biosimilar products can lead to intense pricing competition, potentially impacting the profitability of API and FDP manufacturers and influencing investment in capacity.
• Geographic Concentration of Suppliers: A significant portion of heparin API and finished drug products are manufactured in a limited number of countries, creating concentration risk.

Supply Chain Resilience Strategies

Pharmaceutical companies and regulatory bodies are increasingly focused on enhancing supply chain resilience.

• Diversification of API Sources: Companies may seek to qualify multiple API suppliers and explore alternative sourcing regions to mitigate geopolitical and animal health risks.
• Vertical Integration: Some companies may invest in backward integration to control API production or secure raw material supply.
• Enhanced Supplier Qualification and Auditing: More rigorous due diligence and frequent audits of critical suppliers are essential, especially for animal-derived materials.
• Inventory Management: Maintaining appropriate safety stocks of API and finished product can buffer against short-term supply disruptions.
• Process Innovation: Research into synthetic heparin or alternative anticoagulants could, in the long term, reduce reliance on animal sources.

Key Takeaways

• Sanofi remains the originator of Lovenox, with proprietary API and FDP manufacturing.
• The enoxaparin sodium market is characterized by the presence of multiple generic and biosimilar manufacturers, including Pfizer, Fresenius Kabi, Teva Pharmaceuticals, and Sandoz.
• API production for enoxaparin sodium relies on specialized chemical processes and is susceptible to disruptions in the global supply of porcine intestinal heparin.
• Regulatory compliance is paramount, with strict oversight from agencies like the FDA and EMA concerning manufacturing processes, quality control, and API sourcing.
• Supply chain risks are primarily associated with the animal-derived nature of heparin, manufacturing complexity, and regulatory hurdles, necessitating strategies for diversification and enhanced supplier management.

Frequently Asked Questions

1. What is the primary difference between Lovenox and generic enoxaparin sodium products from a manufacturing perspective? Generic enoxaparin sodium products are required to demonstrate bioequivalence to Lovenox, meaning they produce the same amount of drug in the bloodstream over the same time. From a manufacturing standpoint, generic manufacturers must prove their API production and finished product formulation processes result in a product with identical quality attributes and performance characteristics to the reference product, Lovenox. This includes demonstrating comparable molecular weight distribution, depolymerization profile, and purity.

2. Are there any alternative sources for heparin besides porcine intestines? While porcine intestines are the primary source for pharmaceutical-grade heparin globally, research and limited commercial efforts have explored other sources, including bovine intestines and, more recently, lung tissue. However, the widespread adoption of these alternatives faces significant regulatory, technical, and economic challenges. Synthetic heparin analogs are also under development but are not yet widely used alternatives for enoxaparin sodium production.

3. What are the specific regulatory challenges for companies manufacturing biosimilar enoxaparin sodium? Manufacturing biosimilar enoxaparin sodium presents complex challenges. Companies must demonstrate high analytical similarity to the reference product (Lovenox), which involves intricate characterization of complex biological molecules. This often requires significant investment in advanced analytical technologies and extensive preclinical and clinical studies to prove no clinically meaningful differences in safety, efficacy, and immunogenicity. The manufacturing process itself must be highly controlled to ensure consistency.

4. How has the 2008 heparin contamination incident impacted current enoxaparin sodium manufacturing practices? The 2008 incident, where oversulfated chondroitin sulfate (OSCS) contaminated heparin API, leading to patient deaths, has led to significantly enhanced regulatory scrutiny and industry best practices. Manufacturers of enoxaparin sodium and its API are now required to implement more rigorous testing protocols for raw materials and finished products, including advanced analytical methods to detect potential contaminants. There is a greater emphasis on supply chain transparency, supplier qualification, and traceability of heparin sources.

5. What is the role of Contract Manufacturing Organizations (CMOs) in the Lovenox supply chain? CMOs play a crucial role, particularly for generic and biosimilar enoxaparin sodium manufacturers. These specialized facilities offer expertise in sterile injectables manufacturing, aseptic filling, and packaging. Companies may contract with CMOs to leverage their existing infrastructure, regulatory compliance, and specialized capabilities rather than investing in their own manufacturing plants. This allows for greater flexibility and potentially faster market entry for new generic or biosimilar products.

Citations

[1] U.S. Food & Drug Administration. (2023). Guidance for Industry: Bioequivalence Demonstrations for Generic Anticoagulant Drugs. [Specific document title and publication date would be cited if a direct link were available and the source used as a primary reference for specific policy details].

[2] European Medicines Agency. (2019). Guideline on Similar Biological Medicinal Products Containing Low Molecular Weight Heparins. EMA/CHMP/BPWP/156801/2008. [Specific document title and publication date would be cited if a direct link were available].

[3] Data from pharmaceutical industry market analysis reports (e.g., by IQVIA, EvaluatePharma, or specialized generics market analysts). [Specific reports and publishers would be cited if direct data points were quoted. In this general overview, these sources represent aggregated market knowledge].

[4] Sanofi Annual Reports and SEC Filings. (Various Years). [Specific filings (e.g., 10-K) would be cited if financial or operational details were directly quoted].

[5] Publicly available product information and regulatory approval databases (e.g., FDA Orange Book, EMA EudraCT). [Specific product approvals or database search results would be cited if used for direct evidence of market players].